Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
Coimbra Chemistry Centre, Institute of Molecular Sciences - IMS, Faculty of Sciences and Technology, University of Coimbra, 3004-535 Coimbra, Portugal.
ACS Nano. 2024 Jul 2;18(26):16359-16394. doi: 10.1021/acsnano.4c01790. Epub 2024 Jun 11.
Glioblastoma (GBM) remains the epitome of aggressiveness and lethality in the spectrum of brain tumors, primarily due to the blood-brain barrier (BBB) that hinders effective treatment delivery, tumor heterogeneity, and the presence of treatment-resistant stem cells that contribute to tumor recurrence. Nanoparticles (NPs) have been used to overcome these obstacles by attaching targeting ligands to enhance therapeutic efficacy. Among these ligands, peptides stand out due to their ease of synthesis and high selectivity. This article aims to review single and multiligand strategies critically. In addition, it highlights other strategies that integrate the effects of external stimuli, biomimetic approaches, and chemical approaches as nanocatalytic medicine, revealing their significant potential in treating GBM with peptide-functionalized NPs. Alternative routes of parenteral administration, specifically nose-to-brain delivery and local treatment within the resected tumor cavity, are also discussed. Finally, an overview of the significant obstacles and potential strategies to overcome them are discussed to provide a perspective on this promising field of GBM therapy.
胶质母细胞瘤(GBM)仍然是脑瘤谱中侵袭性和致命性的代表,主要是由于血脑屏障(BBB)阻碍了有效治疗药物的递送、肿瘤异质性和存在治疗抵抗的干细胞,这些都导致肿瘤复发。纳米颗粒(NPs)通过附着靶向配体来提高治疗效果,从而克服了这些障碍。在这些配体中,肽因其易于合成和高选择性而脱颖而出。本文旨在对单配体和多配体策略进行批判性地综述。此外,它还强调了其他策略,这些策略整合了外部刺激、仿生方法和化学方法的影响,作为纳米催化药物,揭示了它们在使用肽功能化 NPs 治疗 GBM 方面的巨大潜力。还讨论了其他给药途径,特别是经鼻脑递药和在切除的肿瘤腔内进行局部治疗。最后,概述了克服这些重大障碍的潜在策略,为 GBM 治疗这一充满希望的领域提供了一个视角。
ACS Nano. 2024-7-2
Adv Healthc Mater. 2024-11
Nanoscale. 2024-5-9
Biomater Adv. 2025-5
Colloids Surf B Biointerfaces. 2024-9
Beilstein J Nanotechnol. 2025-8-5
Biomedicines. 2025-6-9
J Cell Mol Med. 2025-2
Pharmaceutics. 2024-1-11
Adv Drug Deliv Rev. 2024-1
Brain Sci. 2023-10-31
Nanoscale. 2023-12-14
Biosensors (Basel). 2023-9-24
Adv Drug Deliv Rev. 2023-11